The Filing Desk

Caris Life Sciences vs CorVel

Caris Life Sciences CAI · CorVel CRVL · Health Care Services

CorVel reported revenue of $958 million in fiscal 2026, 1.2 times Caris Life Sciences' $812 million in fiscal 2025. Caris Life Sciences' revenue grew 97.0% in its latest year, and CorVel's grew 7.0%. Free cash flow was $67 million at Caris Life Sciences and $110 million at CorVel. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.

Side by side

Caris Life SciencesCorVel
Latest fiscal yearFY2025, Dec 31, 2025FY2026, Mar 31, 2026
Revenue$812M$958M
Revenue growth97.0%7.0%
Revenue growth a year, last 5 years—11.6%
Gross margin—24.3%
Operating margin5.6%—
Net margin−8.4%11.5%
Free cash flow$67M$110M
Free cash flow margin8.2%11.5%
Return on capital——
Net debt to EBITDA−6.2x—
Dividends and buybacks$0M$56M
Change in diluted share count371.0%−0.7%
Last close$18.54$87.36
P/E at the last close—36.7×
Insider trades, last 12 monthsbought $1.5 million, sold $28.9 millionsold $22.5 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Caris Life SciencesCorVel
Operating margin
Percent of revenue
Caris Life SciencesCorVel
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Caris Life SciencesCorVel

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Caris Life Sciences and CorVel pages.